In vitro dissolution testing is a critical tool to control the quality of pharmaceutical products and guide formulation development. However, traditional approaches are often crude, inaccurate measures of actual intestinal release behavior in humans.
The Dynamic Dissolution Model builds upon conventional apparatus but incorporates a unique bicarbonate-based media controlled by a patented Auto pH System™. These innovative features characterize the dynamic environment of the GI tract and modulate parameters crucial to dissolution and drug release. This provides greater in vivo predictive value and the ability to accurately discriminate between formulations.
The gut lumen is a complex and dynamic environment presenting several barriers to oral drug delivery. The variable pH range, plethora of intestinal and bacterial enzymes, and presence of numerous transporters has a significant impact on the solubility, stability, and absorption of drug compounds. Assessing drug behavior throughout the GI tract is a critical pre-formulation step to support candidate selection, and to help design optimal drug delivery systems.
Targeting the End Goal: Opportunities & Innovations in Colonic Drug Delivery
Ranmal, SR, Yadav V, Basit AW. ONdrugDelivery, 2017, Issue 77, pp 22-26.
Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets
Yadav V, Varum F, Bravo R, Furrer E, Bojic D, Basit AW. Transl Res. 2016, 176:38-68.
Animal Farm: Considerations in Animal Gastrointestinal Physiology and Relevance to Drug Delivery in Humans
Hatton GB, Yadav V, Basit AW, Merchant HA. J Pharm Sci. 2015, 104(9):2747-76.
Oral peptide and protein delivery: intestinal obstacles and commercial prospects
Smart AL, Gaisford S, Basit AW. Expert Opin Drug Deliv. 2014, 11(8):1323-35.
Food, physiology and drug delivery
Varum FJ, Hatton GB, Basit AW. Int J Pharm. 2013, 457(2):446-60.
Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery
Freire AC, Basit AW, Choudhary R, Piong CW, Merchant HA. Int J Pharm. 2011, 415(1-2):15-28.
Colonic treatments and targets: issues and opportunities
McConnell EL, Liu F, Basit AW. J Drug Target. 2009, 17(5):335-63.
Gut instincts: explorations in intestinal physiology and drug delivery
McConnell EL, Fadda HM, Basit AW. Int J Pharm. 2008, 364(2):213-26.
The gastrointestinal microbiota as a site for the biotransformation of drugs
Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW. Int J Pharm. 2008, 363(1-2):1-25.
Targeted delivery of probiotics to enhance gastrointestinal stability and intestinal colonisation
Dodoo CC, Wang J, Basit AW, Stapleton P, Gaisford S. Int J Pharm. 2017, 530(1-2):224-229.
A new concept in colonic drug targeting: a combined pH-responsive and bacterially-triggered drug delivery technology
Ibekwe VC, Khela MK, Evans DF, Basit AW. Aliment Pharmacol Ther. 2008, 28(7):911-6.
An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man
McConnell EL, Short MD, Basit AW. J Control Release. 2008, 130(2):154-60.
A dynamic in vitro model to evaluate the intestinal release behaviour of modified-release corticosteroid products
Goyanes A, Hatton GB, Basit AW. JDDST. 2015, 36-42.
Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations
Goyanes A, Hatton GB, Merchant HA, Basit AW. Int J Pharm. 2015, 484(1-2):103-8.
Predicting the gastrointestinal behaviour of modified-release products: utility of a novel dynamic dissolution test apparatus involving the use of bicarbonate buffers
Merchant HA, Goyanes A, Parashar N, Basit AW. Int J Pharm. 2014, 475(1-2):585-91.
Accelerating the dissolution of enteric coatings in the upper small intestine: evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release.
Varum FJ, Merchant HA, Goyanes A, Assi P, Zboranova V, Basit AW. Int J Pharm. 2014, 468(1-2):172-7.
Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products
Liu F, Merchant HA, Kulkarni RP, Alkademi M, Basit AW. Eur J Pharm Biopharm. 2011, 78(1):151-7.
Physiological bicarbonate buffers: stabilisation and use as dissolution media for modified release systems
Fadda HM, Merchant HA, Arafat BT, Basit AW. Int J Pharm. 2009, 382(1-2):56-60.
Gastrointestinal stability of therapeutic anti-TNF α IgG1 monoclonal antibodies
Yadav V, Varum F, Bravo R, Furrer E, Basit AW. Int J Pharm. 2016, 502(1-2):181-7.
Stability of peptide drugs in the colon
Wang J, Yadav V, Smart AL, Tajiri S, Basit AW. Eur J Pharm Sci. 2015, 78:31-6.
Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs
Wang J, Yadav V, Smart AL, Tajiri S, Basit AW. Mol Pharm. 2015, 12(3):966-73.
On the colonic bacterial metabolism of azo-bonded prodrugs of 5-aminosalicylic acid
Sousa T, Yadav V, Zann V, Borde A, Abrahamsson B, Basit AW. J Pharm Sci. 2014, 103(10):3171-5.
Colonic bacterial metabolism of corticosteroids
Yadav V, Gaisford S, Merchant HA, Basit AW. Int J Pharm. 2013, 457(1):268-74.
A paradigm shift in enteric coating: achieving rapid release in the proximal small intestine of man
Liu F, Basit AW. J Control Release. 2010, 147(2):242-5.
A novel concept in enteric coating: a double-coating system providing rapid drug release in the proximal small intestine
Liu F, Lizio R, Meier C, Petereit HU, Blakey P, Basit AW. J Control Release. 2009, 133(2):119-24.
Fabrication and in vivo evaluation of highly pH-responsive acrylic microparticles for targeted gastrointestinal delivery
Kendall RA, Alhnan MA, Nilkumhang S, Murdan S, Basit AW. Eur J Pharm Sci. 2009, 37(3-4):284-90.
Engineering polymer blend microparticles: an investigation into the influence of polymer blend distribution and interaction
Alhnan MA, Basit AW. Eur J Pharm Sci. 2011, 42(1-2):30-6.
Encapsulation of poorly soluble basic drugs into enteric microparticles: a novel approach to enhance their oral bioavailability
Alhnan MA, Murdan S, Basit AW. Int J Pharm. 2011, 416(1):55-60.
Inhibiting the gastric burst release of drugs from enteric microparticles: the influence of drug molecular mass and solubility
Alhnan MA, Cosi D, Murdan S, Basit AW. J Pharm Sci. 2010, 99(11):4576-83.
Drug distribution in enteric microparticles
Nilkumhang S, Alhnan MA, McConnell EL, Basit AW. Int J Pharm. 2009, 379(1):1-8.
The robustness and flexibility of an emulsion solvent evaporation method to prepare pH-responsive microparticles
Nilkumhang S, Basit AW. Int J Pharm. 2009, 377(1-2):135-41.
Copyright © 2018 Intract Pharma
A site by: Web Design London
